All In Biotech

Free tool

FAERS Monitor: Seysara

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209521 or its brand name (Seysara, Sarecycline Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

200

Serious

39

20% of reports

Hospitalization

15

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • headache24
  • drug ineffective14
  • dizziness13
  • vision blurred11
  • rash9
  • off label use8
  • product dose omission issue8
  • pruritus8
  • condition aggravated7
  • fatigue7
  • nausea7
  • anxiety6
  • erythema6
  • migraine6
  • seizure6

Reports by year received

View as table
YearReports
201935
202027
202124
202221
202323
202430
202512
202628

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,959 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
vision blurredSignal118.44.765
migraineSignal66.63.023
seizureSignal65.52.518
headacheSignal244.02.853
erythemaSignal63.11.46
product dose omission issueSignal82.91.58
dizzinessSignal132.71.613
condition aggravatedSignal72.41.25
anxiety62.21.03
pruritusSignal82.21.14
rashSignal92.21.15
drug ineffective141.10.70
off label use81.00.50
fatigue70.90.50
nausea70.90.40

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.